Rituximab-vemurafenib combination for the treatment of relapsed/Refractory hairy cell leukemia
MetadataShow full item record
CitationSevindik, Ö., Gemici, A., Mutlu, Y. G., Balık Aydın, B. ve Çakır, A. (2020). Rituximab-vemurafenib combination for the treatment of relapsed/Refractory hairy cell leukemia. Clinical Lymphoma, Myeloma & Leukemia içinde (S286-S286. ss.).
Objective: The management of R/R-HCL is not standardized yet. Patients with HCL universally harbor BRAF mutations, which makes BRAF inhibitors a potential treatment approach. The effi cacy and safety of the BRAF inhibitor Vemurafenib were evaluated both as a single-agent option in two phase 2 trials and also combined with Rituximab in another phase 2 trial. Patients: We have decided to present the fi rst two consecutive patients who achieved a rapid and prolonged response, relapsing after treatment with purine analogues. The fi rst two patients who received a combination of R-V for R/R HCL from the records of our institutional CLPD registry were reported.
WoS Q KategorisiQ3
SourceClinical Lymphoma, Myeloma & Leukemia
- Bildiri Koleksiyonu 
- WoS İndeksli Yayınlar Koleksiyonu